Safety of newer disease modifying therapies in multiple sclerosis
G Jalkh, R Abi Nahed, G Macaron, M Rensel - Vaccines, 2020 - mdpi.com
In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies
TE Smith, I Kister - Current neurology and neuroscience reports, 2021 - Springer
Abstract Purpose of Review The newer, higher-efficacy disease-modifying therapies (DMTs)
for multiple sclerosis (MS)—orals and monoclonals—have more profound …
for multiple sclerosis (MS)—orals and monoclonals—have more profound …
Vaccination of multiple sclerosis patients during the COVID-19 era: novel insights into vaccine safety and immunogenicity
E Kim, A Haag, J Nguyen, MM Kesselman… - Multiple Sclerosis and …, 2022 - Elsevier
Multiple sclerosis (MS) is an incurable autoimmune disease known to cause widespread
demyelinating lesions in the central nervous system (CNS) and a host of debilitating …
demyelinating lesions in the central nervous system (CNS) and a host of debilitating …
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment
S Otero-Romero, A Sánchez-Montalvá… - Expert Review of …, 2021 - Taylor & Francis
Introduction: The important development that the multiple sclerosis (MS) treatment field has
experienced in the last years comes along with the need of dealing with new adverse events …
experienced in the last years comes along with the need of dealing with new adverse events …
Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers
I Adamec, GB Jakob, C Rajda, J Drulović… - Journal of …, 2023 - Elsevier
Background Cladribine is an oral disease-modifying drug authorized by the European
Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS) …
Medicine Agency for the treatment of highly active relapsing multiple sclerosis (MS) …
[PDF][PDF] Safety of newer disease modifying therapies in multiple sclerosis. Vaccines. 2021; 9: 12
G Jalkh, R Abi Nahed, G Macaron, M Rensel - 2020 - pdfs.semanticscholar.org
In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
[HTML][HTML] Fingolimod induced fulminant liver failure requiring liver transplantation: A case report
Fingolimod has been used for about ten years to treat multiple recurrent sclerosis. It has
been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the …
been reported that Fingolimod causes an elevation in liver enzymes. In this case report, the …